ibrutinib,zanubrutinib
abbvie,beigene,janssen
['leukemia', 'zanubrutinib', 'cll', ' ibru', 'alpine']
dana-farber's jennifer brown, md, phd, says the phase 3 alpine randomized trial shows the drug zanubrutinib is superior to ibrutinib in relapsed/refractory chronic lymphocytic leukemia and should be considered a new standard of care in this setting. #ash22 #cll 
Dana-Farber Cancer Institute - a leading center for expert, compassionate cancer care and advanced research.
Appts: 877-442-3324 | https://t.co/HvCwkLltic